Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction successfully treated by infarct related artery (IRA) successful revascularization~* Male and female patients, aged 18-80 years~* Large myocardial injury as demonstrated by LVEF ≤45% and/or infarct size (IS) ≥10% of the LV muscle on cMRI 2-5 days after pPCI~* Signed informed consent~Exclusion Criteria:~* Pacemaker or other contraindications to cardiac MRI~* Malignancy~* Moderate or severe immunodeficiency~* Acute or chronic bacterial or viral infectious disease~* Soft tissue disease or local infection in a place of required artery puncture~* Pregnancy or breastfeeding~* Any objective or subjective reason for inability to attend follow-up visits~* Females of childbearing potential, who does not want to use a highly effective method of contraception~* Females of childbearing potential who does not have a menstrual period confirmed and a negative highly sensitive urine or serum pregnancy test~* Participation in any other clinical research study that has not reached the primary efficacy endpoint or otherwise would interfere with the patient's participation in this project~* Life expectancy \< 1 year~* Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the project

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active Group (Type: EXPERIMENTAL): Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
- Control Group (Type: PLACEBO_COMPARATOR): Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).